PL3292145T3 - Mutanty fc ze zmodyfikowaną aktywnością funkcjonalną - Google Patents
Mutanty fc ze zmodyfikowaną aktywnością funkcjonalnąInfo
- Publication number
- PL3292145T3 PL3292145T3 PL16726133.8T PL16726133T PL3292145T3 PL 3292145 T3 PL3292145 T3 PL 3292145T3 PL 16726133 T PL16726133 T PL 16726133T PL 3292145 T3 PL3292145 T3 PL 3292145T3
- Authority
- PL
- Poland
- Prior art keywords
- mutants
- functional activity
- modified functional
- modified
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1554101A FR3035879B1 (fr) | 2015-05-07 | 2015-05-07 | Mutants fc a activite fonctionnelle modifiee |
| PCT/FR2016/051068 WO2016177984A1 (fr) | 2015-05-07 | 2016-05-06 | MUTANTS Fc A ACTIVITÉ FONCTIONNELLE MODIFIÉE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3292145T3 true PL3292145T3 (pl) | 2025-06-09 |
Family
ID=54151308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16726133.8T PL3292145T3 (pl) | 2015-05-07 | 2016-05-06 | Mutanty fc ze zmodyfikowaną aktywnością funkcjonalną |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11649271B2 (pl) |
| EP (1) | EP3292145B1 (pl) |
| JP (1) | JP6830903B2 (pl) |
| KR (2) | KR20240116586A (pl) |
| CN (2) | CN115073604A (pl) |
| AU (2) | AU2016259124B2 (pl) |
| CA (1) | CA2977010A1 (pl) |
| DK (1) | DK3292145T3 (pl) |
| ES (1) | ES3014454T3 (pl) |
| FR (1) | FR3035879B1 (pl) |
| MX (1) | MX2017013028A (pl) |
| PL (1) | PL3292145T3 (pl) |
| WO (1) | WO2016177984A1 (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3035879B1 (fr) | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| KR102777127B1 (ko) | 2016-08-02 | 2025-03-07 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| CN109863170B (zh) | 2016-08-12 | 2024-08-16 | 詹森生物科技公司 | 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子 |
| FR3064007A1 (fr) | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps pour le traitement de cancers |
| FR3075200B1 (fr) * | 2017-12-15 | 2022-12-23 | Lab Francais Du Fractionnement | Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc |
| MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
| JP7372237B2 (ja) * | 2018-06-04 | 2023-10-31 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
| CN112566929A (zh) * | 2018-08-21 | 2021-03-26 | 生物蛋白有限公司 | 具pH选择性的条件活性蛋白质 |
| KR20210131373A (ko) * | 2019-02-18 | 2021-11-02 | 커리어 테라퓨틱스, 인코포레이티드. | 오르토폭스바이러스 주요 조직적합성 복합체(mhc) 클래스 i-유사 단백질(omcp) 및 종양-특이 결합 파트너를 사용한 이중특이적 융합 단백질 |
| CA3177604A1 (en) * | 2020-04-17 | 2021-10-21 | Janssen Biotech, Inc. | Biosynthetic glycoprotein populations |
| EP4225787A4 (en) * | 2020-05-21 | 2024-10-23 | Zydus Lifesciences Limited | FC VARIANT AND PRODUCTION THEREOF |
| CN113186167B (zh) * | 2021-04-28 | 2021-11-30 | 中国食品药品检定研究院 | 用于测定抗cd20单克隆抗体药物adcp生物学活性的方法 |
| WO2024005424A1 (ko) * | 2022-06-29 | 2024-01-04 | 고려대학교 산학협력단 | FCγRIIA 결합 선택성이 향상된 인간 FC 변이체 |
| EP4608515A1 (en) | 2022-10-25 | 2025-09-03 | Seismic Therapeutic, Inc. | Variant igg fc polypeptides and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
| EP1587540B1 (en) * | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
| BRPI0517837A (pt) * | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| KR101808602B1 (ko) * | 2009-10-07 | 2017-12-13 | 마크로제닉스, 인크. | 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법 |
| PL2536745T3 (pl) * | 2010-02-19 | 2017-01-31 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| EP2537864B1 (en) * | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| FR3012453B1 (fr) * | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| FR3035879B1 (fr) | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
-
2015
- 2015-05-07 FR FR1554101A patent/FR3035879B1/fr active Active
-
2016
- 2016-05-06 ES ES16726133T patent/ES3014454T3/es active Active
- 2016-05-06 US US15/554,022 patent/US11649271B2/en active Active
- 2016-05-06 WO PCT/FR2016/051068 patent/WO2016177984A1/fr not_active Ceased
- 2016-05-06 CA CA2977010A patent/CA2977010A1/en active Pending
- 2016-05-06 DK DK16726133.8T patent/DK3292145T3/da active
- 2016-05-06 KR KR1020247024678A patent/KR20240116586A/ko not_active Ceased
- 2016-05-06 PL PL16726133.8T patent/PL3292145T3/pl unknown
- 2016-05-06 MX MX2017013028A patent/MX2017013028A/es unknown
- 2016-05-06 JP JP2017554315A patent/JP6830903B2/ja active Active
- 2016-05-06 CN CN202210707722.5A patent/CN115073604A/zh active Pending
- 2016-05-06 EP EP16726133.8A patent/EP3292145B1/fr active Active
- 2016-05-06 CN CN201680025478.7A patent/CN107531794B/zh active Active
- 2016-05-06 KR KR1020177031051A patent/KR102689154B1/ko active Active
- 2016-05-06 AU AU2016259124A patent/AU2016259124B2/en active Active
-
2022
- 2022-09-08 AU AU2022228151A patent/AU2022228151B2/en active Active
-
2023
- 2023-03-31 US US18/193,830 patent/US20230265155A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022228151A1 (en) | 2022-09-29 |
| ES3014454T3 (en) | 2025-04-22 |
| EP3292145A1 (fr) | 2018-03-14 |
| KR20180004125A (ko) | 2018-01-10 |
| WO2016177984A1 (fr) | 2016-11-10 |
| CN115073604A (zh) | 2022-09-20 |
| AU2016259124A1 (en) | 2017-08-31 |
| AU2022228151B2 (en) | 2025-06-26 |
| US20180030111A1 (en) | 2018-02-01 |
| CA2977010A1 (en) | 2016-11-10 |
| EP3292145B1 (fr) | 2025-01-08 |
| FR3035879A1 (fr) | 2016-11-11 |
| JP2018515446A (ja) | 2018-06-14 |
| JP6830903B2 (ja) | 2021-02-17 |
| DK3292145T3 (da) | 2025-03-31 |
| BR112017023453A2 (pt) | 2018-07-31 |
| CN107531794B (zh) | 2022-07-12 |
| AU2016259124B2 (en) | 2022-06-16 |
| FR3035879B1 (fr) | 2025-02-28 |
| MX2017013028A (es) | 2017-12-08 |
| US11649271B2 (en) | 2023-05-16 |
| CN107531794A (zh) | 2018-01-02 |
| KR102689154B1 (ko) | 2024-07-29 |
| US20230265155A1 (en) | 2023-08-24 |
| KR20240116586A (ko) | 2024-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3292145T3 (pl) | Mutanty fc ze zmodyfikowaną aktywnością funkcjonalną | |
| ZA201704562B (en) | Picolinamides with fungicidal activity | |
| GB2591662B (en) | Headgear assemblies and interface assemblies with headgear | |
| PL3250692T3 (pl) | Promotor i jego zastosowania | |
| EP3160221A4 (en) | Row unit with tracks | |
| GB201407288D0 (en) | Activity monitors | |
| IL249511B (en) | Novel p450–bm3 variants with enhanced activity | |
| AP2016009385A0 (en) | Lancet assembly | |
| IL256441B (en) | New p450–bm3 variants with enhanced activity | |
| PL3481865T3 (pl) | Mutanty fc o ulepszonej aktywności funkcjonalnej | |
| PL3430031T3 (pl) | Peptydy o aktywności przeciwnowotworowej | |
| PT3174978T (pt) | Proteína com atividade de dextrano-sacarase e utilizações | |
| GB201420952D0 (en) | Head unit with interchangeble functional bezel | |
| PL3383851T3 (pl) | Pochodne dekstrorfanu o stłumionej nerwowej aktywności ośrodkowej | |
| PL3303243T3 (pl) | Lustro o ulepszonej trwałości | |
| EP3279323A4 (en) | Amadoriase having improved specific activity | |
| GB201520417D0 (en) | Trenchcover with retainer | |
| GB201416411D0 (en) | Trenchcover with retainer | |
| GB201412808D0 (en) | Furniture assembly | |
| GB201414475D0 (en) | Touch tec | |
| TWM488921U (en) | Chair with reminding function |